Beta-catenin expression and effect on long-term survival in advanced epithelial ovarian cancer

2016 ◽  
Author(s):  
Bence Nagy
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Beta Catenin ◽  
Term Survival ◽  
Long Term Survival ◽  
Advanced Epithelial Ovarian Cancer

Nuclear β-catenin positivity as a predictive marker of long-term survival in advanced epithelial ovarian cancer

2017 ◽  
Vol 213 (8) ◽  
pp. 915-921 ◽  
Author(s):  
Bence Nagy ◽  
László Tóth ◽  
Péter Molnár ◽  
Gábor Méhes ◽  
László Thurzó ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Predictive Marker ◽  
Term Survival ◽  
Long Term Survival ◽  
Advanced Epithelial Ovarian Cancer

scholarly journals Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer

2017 ◽  
Vol 116 (7) ◽  
pp. 964-971 ◽  
Author(s):  
Shana J Kim ◽  
Barry Rosen ◽  
Isabel Fan ◽  
Anna Ivanova ◽  
John R McLaughlin ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Term Survival ◽  
Long Term Survival ◽  
Epidemiologic Factors

scholarly journals The association between lymph node metastases and long-term survival in patients with epithelial ovarian cancer

2020 ◽  
Vol 24 (3) ◽  
pp. 163-171
Author(s):  
Katarzyna Lepinay ◽  
Sebastian Szubert ◽  
Agnieszka Lewandowska ◽  
Tomasz Rajs ◽  
Krzysztof Koper ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Lymph Node ◽  
Epithelial Ovarian Cancer ◽  
Lymph Node Metastases ◽  
Term Survival ◽  
Long Term Survival ◽  
Node Metastases

Long-Term Survival and Cost of Treatment in Patients with Stage IIIC Epithelial Ovarian Cancer

2009 ◽  
Vol 5 (1) ◽  
pp. 44-50 ◽  
Author(s):  
Leniaud Louis ◽  
Sifer Christophe ◽  
Amy Cooper ◽  
David Nelson ◽  
Stacy Doran ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Stage Iiic ◽  
Cost Of Treatment ◽  
Term Survival ◽  
Long Term Survival

Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer

2007 ◽  
Vol 17 (5) ◽  
pp. 986-992 ◽  
Author(s):  
M. O. Nicoletto ◽  
S. Tumolo ◽  
R. Sorio ◽  
G. Cima ◽  
L. Endrizzi ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Overall Survival ◽  
Epithelial Ovarian Cancer ◽  
Residual Disease ◽  
Randomized Study ◽  
Disease Free Survival ◽  
Term Survival ◽  
Long Term Survival ◽  
Disease Free

The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was <2 cm in 61 patients without platinum, 59 with platinum. Median age was 58 years in nonplatinum arm and 55 years in platinum arm (range: 15–73). Complete and partial responses were 51% and 10% for nonplatinum arm and 51% and 8% for platinum arm, respectively (P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor.

Sign in / Sign up

Export Citation Format

Share Document